Advertisement
Canada markets close in 37 minutes

  • S&P/TSX

    21,868.87
    -142.85 (-0.65%)
     

  • S&P 500

    5,073.65
    +3.10 (+0.06%)
     

  • DOW

    38,485.52
    -18.17 (-0.05%)
     

  • CAD/USD

    0.7302
    -0.0019 (-0.25%)
     

  • CRUDE OIL

    82.92
    -0.44 (-0.53%)
     

  • Bitcoin CAD

    87,974.13
    -3,273.09 (-3.59%)
     

  • CMC Crypto 200

    1,385.02
    -39.08 (-2.75%)
     

  • GOLD FUTURES

    2,335.10
    -7.00 (-0.30%)
     

  • RUSSELL 2000

    1,989.37
    -13.27 (-0.66%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ

    15,716.79
    +20.15 (+0.13%)
     

  • VOLATILITY

    15.99
    +0.30 (+1.91%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6819
    -0.0017 (-0.25%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Stocks in play: BELLUS Health Inc.

Baystreet.ca
Updated

Announced the appointment of a world-class clinical advisory board. The CAB will provide strategic guidance and support to the development of BLU-5937, BELLUS Health's lead drug candidate for chronic cough, as the Company prepares for a clinical Phase 2 study. BLU-5937 is currently in a clinical Phase 1 study and results are expected in the fourth quarter of 2018. The first meeting of the CAB was held on September 24 in London, England. BELLUS Health Inc. shares T.BLU are trading up $0.04 at $1.07.